Read the March Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Does Castrate in Prostate Cancer Need Revision?
  • Adjuvant Docetaxel No Help in High-Risk Prostate Cancer
  • AS Safe for Prostate Cancer Patients Under 60 Years Old
  • Time Interval to Biochemical Failure – Surrogate End Point?
  • PCa Death Risk Linked to Post EBRT Time to PSA Nadir
  • Doc Moyad’s Column: “Follow Breast Cancer for Lifestyle?!”
  • Fusion Biopsies in AS Predict Prostate Cancer Progression
  • QoL But Sexual Dysfunction Common After Prostate Cancer
  • Low Carb Diet & Walking May Ease Adverse Effects of ADT
  • Doctor Chodak’s Bottom Line
  • Adding MRI Does Not Boost Prostate Cancer Upgrading

Posted in Uncategorized by with no comments yet.

Read the February Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • RP Beats Surveillance, or Does It?
  • Overactive Bladder Linked to ADT for Prostate Cancer
  • New, Quicker Test to Assess Risk of PCa Metastasis
  • Short- vs. Intermediate-Term AS with RT & Zoledronic Acid
  • Doc Moyad’s Column: “Restaurants = Weight Gain?!”
  • PCa Risk Higher in Men with Inflammatory Bowel Disease
  • Hypofractionated RT & Pca
  • Combination Strategy IDs Pca
  • Gleason 6 PCa More Lethal in Black Men
  • Gold Nanoparticles Could Destroy Prostate Cancer
  • Survival – Black vs. White Men Receiving Docetaxel
  • Surrogate Marker for ADT
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.

Read the January Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Prostatectomy Beats Active Surveillance Long Term – or Does It?
  • Is No Surgery Feasible in Gleason 9 and 10 PCa?
  • Prostate Cancer Risk Lower in Long-Term Users of Lipid-Lowering Drugs
  • YouTube Videos Often Mislead on Prostate Cancer
  • Doc Moyad’s No Bogus Science: “Are Fish Oil Results a Little Fishy?!”
  • ADT May Be Less Beneficial for Gleason Score 9 to 10 Prostate Cancer
  • Doctor Chodak’s Bottom Line
  • Index of Articles Published in the 2018 Hot SHEET

Posted in Uncategorized by with no comments yet.

Read the December Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Adding Radium-223 to Abiraterone No Help in Prostate Cancer
  • New Data on RT in Prostate Cancer Are “Practice Changing”
  • ADT plus Pelvic Node RT & Freedom from Prostate Cancer Progression
  • Better Outcomes with RT for Black Prostate Cancer Patients
  • Doc Moyad’s No Bogus Science: “VITAL = the End of the Vitamin D Debate? Nope!!”
  • CyberKnife® SBRT Results From 38 Institutions in More than 500 Men Followed Over Seven Years
  • Agent Orange Exposure Does Not Appear to Worsen Prostate Cancer Outcomes
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.

Read the Us TOO November Hotsheet

Click here to read these short Hotsheet articles:

  • PCa Detection in Men 70 and Older Cost Medicare $1.2B Every 3 Years
  • Dismissing Reduced Abiraterone Dose is Absolutely Wrong
  • Can Aspirin Help Treat Cancer?
  • Simple Clinical Factors May Aid Prognosis in Non-Metastatic CRPC
  • Bladder Cancer Risk Higher With Radiation Therapy for Prostate Cancer
  • Doc Moyad’s No Bogus Science: “Low-Dose Aspirin Dangerous? Yup!”
  • Apalutamide Treatment In Metastatic Castration-Resistant Prostate Cancer
  • Immunotherapy Could Offer Hope for Men with Aggressive Prostate Cancers
  • Surgery and Radiation for Advanced Prostate Cancer Offers Better Survival
  • High Mutation Load Seen in the High- Risk Prostate Tumors of African Men
  • Doctor Chodak’s Bottom Line
  • Study Private Payer Coverage of Prostate MRI Lagging

Posted in Uncategorized by with no comments yet.

Read the Us TOO October Hotsheet

Click here to read these short Hotsheet articles:

  • Prostate cancer Screening Has No Effect on Overall Mortality
  • LDR Brachytherapy Beneficial in High-Risk Prostate Cancer
  • Nuclear Pore Proteins May Be Effective Anticancer Targets for PCa
  • PSA Testing Initiation and Shared Decision-Making
  • Clinical Utility of Total Length Gleason Pattern 4 on Biopsy
  • Doc Moyad’s No Bogus Science: “No Safe Level of Alcohol?! What!?!
  • Men’s Eating and Living (MEAL) Study (CALGB 70807 Alliance)
  • Long-Term Outcomes After Deferred RP with Initial AS Treatment
  • Impact of Family History of Cancer on Risk and Mortality of Second Cancers
  • Experts Find Flaw in Prostate Cancer PET Imaging Technique
  • Prostate Cancer Radiotherapy Effective Long-Term
  • Obese Prostate Cancer Patients Do Worse After RP
  • SBRT Appears Effective for Oligometastatic Prostate Cancer
  • Test Panel Shows 94% Accuracy in Detecting Aggressive PCa
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.

September is Prostate Cancer Awareness Month!

Do what you can to increase public awareness of the importance of prostate health and screenings, educating about risk factors and symptoms, and advocating for further research on prostate health issues.  Get the word out in any way that you can!


Posted in Uncategorized by with no comments yet.

Read the Us TOO September Hotsheet

Click here to read these short Hotsheet articles:

  • Shorter ADT Course May Suffice for High-Risk Prostate Cancer
  • Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
  • No Benefit of Adding Abiraterone to Enzalutamide in Metastatic CRPC
  • Cost Effectiveness of SelectMDx in Prostate Cancer Risk Assessment
  • Proton Therapy Trials “At Risk,” Slow to Enroll Patients
  • Doc Moyad’s No Bogus Science: “Artificially Sweetened Beverages…”
  • Aggressive Prostate Cancer Type is “Fairly Prevalent”
  • Androgen Deprivation Therapy Ups Risk of a Thromboembolic Event
  • MRI-Targeted Biopsies May Have a Role in Active Surveillance
  • Large US Study Targets Prostate Cancer in Black Men
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.

Read the Us TOO August Hotsheet

Click here to read these short Hotsheet articles:

  • Prostvac-V/F Vaccine Found Not to Improve Survival
  • DNA Test Identified Men with Six-Fold Increased Risk of Prostate Cancer
  • Enzalutamide Postpones Metastasis for a Subset of High-Risk PCa Patients
  • Phase III Trial Between Adjuvant Docetaxel and Surveillance
  • Statin Use and Time to Progression in Men on Active Surveillance for PCa
  • Doc Moyad’s No Bogus Science: “The Final Verdict on Coffee is… You?!
  • Novel Assay Can Guide Therapy in Advanced Prostate Cancer
  • Metformin Added to ADT for Prostate Cancer Ups Survival
  • Complications from Prostate Biopsy Deter Men from Re-Biopsy
  • CDK12 Variants and Vulnerability to Immune Checkpoint Inhibitors
  • Finasteride Safely Prevents PCa
  • Androgen Deprivation Therapy is Associated With Prolongation of QTc Interval in Men with Prostate Cancer
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.

Read the Us TOO July Hotsheet

Click here to read these short Hotsheet articles:

  • No Survival Bump for Localized PCa with More Frequent PSA Tests
  • Notable Differences with Three Prostate Cancer Genomic Tests
  • Black Men Do Well in Prostate Cancer Trials
  • IsoPSA Test Could Reduce Overdiagnosis/Overtreatment in PCa
  • Laser Focal Ablation of Prostate Cancer Improves Outcomes
  • Doc Moyad’s No Bogus Science:- “Eight Glasses of Water Per Day?!”
  • No Immediate Treatment for Low-Risk Prostate Cancer
  • Prostate Cancer Survival Odds Worse for Smokers
  • This “Metastasis-Blocking” Compound Could Stop the Spread of Cancer
  • Abiraterone May Be More Effective in Black Men with Advanced PCa
  • Adjuvant Docetaxel Fails in Higher-Risk Prostate Cancer
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.